| Drug name | PC-AB-009 |
| Overview | PC-AB-009 is a humanized monoclonal antibody targeting Claudin 18.2 for treating the patient of Claudin 18.2-positive malignant tumor. PC-AB-009 specifically binds to claudin 18.2 with high affinity to activate antibody-dependent cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). In addition, PC-AB-009 enhances T-cell infiltration and induce pro-inflammatory cytokines. |
| Target | Claudin 18 is a member of the claudin family of tight junction proteins. Its two isomers are Claudin 18.1 and Claudin 18.2. Claudin 18.2 is often overexpressed in gastric, pancreatic, lung and other solid tumors. The high expression of Claudin 18.2 plays an important role in the metastasis and growth of tumor cells. Exposed extracellular loops, Claudin 18.2 is available for monoclonal antibody binding. These biological characteristics suggested that it is an ideal molecule for targeted therapy. |
| Indication | Gastric cancer is the fifth leading type of cancer and the third leading cause of death from cancer, making up 7% of cases and 9% of deaths. In 2018, it newly occurred in 1.03 million people and caused 783,000 deaths. Gastric cancer usually has a poor prognosis because the tumor often metastasizes at the time of discovery, and the median age of patients with the disease is between 70 and 75 years. Pancreatic cancer is among the most deadly of all malignancies, with a five-year survival rate of less than 10%. Currently the fourth leading cause of cancer mortality worldwide, some estimate that it could move up to second place in the next decade. More than 90% of all pancreatic cancers are pancreatic ductal adenocarcinomas, which are extremely aggressive and typically diagnosed at the advanced stage. |